Brain damage from anticancer treatments in adults

Area of Science:

• Neuro-oncology
• Radiation oncology
• Medical oncology

Background:

• Treatment-induced brain toxicity is a significant concern for adult cancer patients.
• The exact cause of brain damage (vascular vs. parenchymal) remains debated.
• Despite methodological advances, clinical trials often fail to fully elucidate treatment effects on brain function.

Purpose of the Study:

• To review current understanding of cancer treatment-induced brain toxicity.
• To identify responsible treatment modalities and impaired brain functions.
• To determine patient vulnerability and duration of cognitive impairment.

Main Methods:

• Review of recent prospective clinical trials on brain toxicity.
• Analysis of methodological designs in published studies.
• Questioning of current study methodologies and suggestions for future trials.

Main Results:

• Safer radiation techniques have emerged, but combined radiotherapy-chemotherapy use has increased.
• Subtle cognitive dysfunction (e.g., radiation-induced leukoencephalopathy) is increasingly reported, replacing classic radionecrosis.
• Chemotherapy, alone or combined, also contributes to neurotoxicity.

Conclusions:

• Brain toxicity is clinically significant for brain tumor patients and those at risk for metastasis.
• Prophylactic cranial irradiation may benefit high-risk patients.
• Systemic cancer drugs, even for non-brain tumors, can impair normal brain function.